Question 1

What is LAPATINIB used for?

Accepted Answer

LAPATINIB (brand name Lapatinib) is a Other indicated for including an anthracycline, a taxane, including an anthracycline.

Question 2

How does LAPATINIB work?

Accepted Answer

LAPATINIB works through the following mechanism: 12.1 Mechanism of Action Lapatinib is a 4-anilinoquinazoline kinase inhibitor of the intracellular tyrosine kinase domains of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors (estimated Ki app values of 3nM and 13nM, respectively) with a dissociation half-life of greater than or equal to 300 minutes. Lapatinib inhibits ErbB-driven tumor cell growth in vitro and in various animal models. An additive effect was demonstrated in an in vitro study when lapatinib and 5-FU (the active metabolite of capecitabine) were used in combination in the 4-tumor cell lines tested. The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines. Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro . These in vitro findings suggest non-cross-resistance between these two agents. Hormone receptor-positive breast cancer.

Question 3

What are the most common side effects of LAPATINIB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for LAPATINIB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is LAPATINIB the same as Lapatinib?

Accepted Answer

Lapatinib is a brand name for LAPATINIB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

LAPATINIB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations